Clinical Practice Session
Small Clone, Big Consequences: Treating Monoclonal Gammopathy of Renal Significance in the Modern Era
October 24, 2026 | 02:00 PM - 04:00 PM
Location: Room 107, Convention Center
Session Description
Monoclonal gammopathy of renal significance (MGRS) presents unique therapeutic challenges at the intersection of nephrology and hematology. This session reviews contemporary approaches to clone-directed therapy, focusing on treatment indications, regimen selection, response assessment, and care coordination to improve kidney outcomes while balancing hematologic risk.
Support for all sessions in the Glomerular Diseases Learning Pathway is provided by an educational grant from Vera Therapeutics, Inc.
Learning Objective(s)
- Compare available treatment strategies for plasma cell- and B cell-driven MGRS, including proteasome inhibitors, immunotherapies, and emerging targeted agents
- Describe principles of treatment selection and response assessment to optimize kidney outcomes while minimizing therapy-related toxicity
- Identify kidney biopsy and hematologic features that indicate the need for clone-directed therapy in patients with MGRS
Learning Pathway(s)
- Glomerular Diseases
- Onconephrology
Moderators
Presentations
- Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits with and Without an Associated Monoclonal Gammopathy
02:00 PM - 02:30 PM
- Beyond the Glomeruli: Tubular Toxicity of Monoclonal Proteins
02:30 PM - 03:00 PM
- Membranous-Like Glomerulopathy: A MGRS Mimicker
03:00 PM - 03:30 PM
- Treating Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits: Comparing Combination Chemotherapy with CD38 Monotherapy
03:30 PM - 04:00 PM